Neurology encompasses deep brain stimulation, spinal cord stimulation, peripheral nerve therapies and an expanding pipeline of closed-loop and adaptive technologies: some of the most cutting edge technologies not only in healthcare, but across the entire technology landscape.
The neurological disease burden is accelerating demand for advanced therapeutic technologies. WHO identifies neurological conditions as the world’s leading cause of illness and disability, affecting more than 1 in 3 people globally. Within this landscape, the neurostimulation devices market was valued at $8.1 billion in 2024 and is projected to reach $25.2 billion by 2034, expanding at a CAGR of 12.1%
Utilizing electrical energy or chemical agents, regulated healthcare technology businesses are able to influence the body’s nerve activity, achieving results ranging from reducing chronic pain and headaches to enabling paralysed patients to communicate. The market remains highly concentrated, with Medtronic, Abbott, and Boston Scientific estimated to account for approximately 65-70% of global market revenue. The next frontier of innovation is increasingly being shaped by a wave of smaller, highly specialized companies developing advanced platforms across bioelectronic medicine, AI-driven stimulation, closed-loop neuromodulation, and brain-computer interfaces.